Superseded public profile

FDA-approved↗Metabolic↗

Superseded · version 2: Lixisenatide↗

Related names recorded in this version: Soliqua 100/33↗

A GLP-1 receptor agonist component. This profile cites a U.S. combination-product label.↗

This is preserved historical wording.
It is no longer the current profile. Read the canonical profile and its correction notice.
Update · July 27, 2026

We rewrote the profile summary to describe the cited public record more directly. The cited sources and status did not change. 1

What this version reported

The cited DailyMed label identifies Lixisenatide and contains the product's official indications and warnings. This profile links to the label without restating it as medical guidance.↗

Organizations named in cited records:
  • U.S. National Library of Medicine↗

Sources for this version

  1. 1
    SOLIQUA 100/33 (insulin glargine and lixisenatide) injection · SPL version 25 · published 2026-03-20 ↗

    DailyMed · U.S. National Library of Medicine · Official source · Source checked July 22, 2026